pipette
ESEspañol

Dual-action small-molecule VSP-51-2 ameliorates polycystic ovary syndrome via PPARγ modulation and AKR1C3 inhibition

Xiawen Liu, Xiufen Zheng, Lei Ma, Ziqing Yao, Xuehua Zheng, Miao Liang, Xinhong Wu, Silin Zhang, Xianglin Zhou, Leying Zhu, Zhi Zhou, H. Eric Xu, Wei Yi

Peer-reviewed journal

In the authors' words

This journal does not let us republish the full abstract. Here are the two sentences Pipette selected, quoted from it. Read the rest at the publisher.

Main result
We report VSP-51-2, a dual-target lead compound initially engineered as a selective PPARγ modulator that unexpectedly exerts potent uncompetitive inhibition of the androgen-synthesizing enzyme AKR1C3 through a putative allosteric mechanism.

Appeared: Friday, November 13. Science Advances. Peer-reviewed journal.

DOI: 10.1126/sciadv.aee9754